article thumbnail

Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half

DAIC

milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.

article thumbnail

Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial

Frontiers in Cardiovascular Medicine

After treatment, three-months major adverse cardiovascular events (MACE) were assessed as the primary outcome. This therapeutic effect is likely due to the active components of FFDS targeting key proteins: LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT.Clinical Trial Registration[link] identifier (ChiCTR2400080149).

article thumbnail

2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation

Circulation, Ahead of Print.

article thumbnail

Circulating growth differentiation factor‐15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: A 20‐year follow‐up study

European Journal of Heart Failure

The (+) and () signs mean that the variable has a positive or a negative association with growth differentiation factor-15 (GDF-15) levels in the fully adjusted model (age, gender, current smoker, body mass index, total cholesterol, systolic blood pressure and N-terminal pro-B-type natriuretic peptide), respectively.

article thumbnail

Flipped C-Terminal Ends of apoA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs

Circulation

Circulation, Ahead of Print. BACKGROUND:Cholesterol efflux capacity (CEC) predicts cardiovascular disease independently of high-density lipoprotein (HDL) cholesterol levels. Despite their very low plasma levels of HDL particles, these subjects had normal CEC.

article thumbnail

Harnessing RNA Interference for Cholesterol Lowering: The Bench?to?Bedside Story of Inclisiran

Journal of the American Heart Association

Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Twice‐yearly maintenance subcutaneous inclisiran (following initial loading doses at Day 1 and Day 90) reduces circulating LDL‐C levels by ≈50% versus placebo when added to maximally tolerated statins.

article thumbnail

Link between high levels of niacin -- a common b vitamin -- and heart disease, study suggests

Science Daily - Heart Disease

Researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heart disease.